PubRank

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

PubWeight™: 3.21‹?› | Rank: Top 1%

🔗 View Article (PMID 28538134)

Published in N Engl J Med on May 24, 2017

Authors

Orrin Devinsky1, J Helen Cross1, Linda Laux1, Eric Marsh1, Ian Miller1, Rima Nabbout1, Ingrid E Scheffer1, Elizabeth A Thiele1, Stephen Wright1, Cannabidiol in Dravet Syndrome Study Group

Author Affiliations

1: From the New York University Langone Comprehensive Epilepsy Center, New York (O.D.); the University College London Great Ormond Street Institute of Child Health (J.H.C.) and GW Pharmaceuticals (S.W.) - both in London; Lurie Children's Epilepsy Center, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago (L.L.); the Children's Hospital of Philadelphia, Philadelphia (E.M.); Miami Children's Hospital, Miami (I.M.); Hôpital Necker-Enfants Malades, Paris (R.N.); Florey Institute, Austin Health and Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia (I.E.S.); and Massachusetts General Hospital, Boston (E.A.T.).

Associated clinical trials:

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) | NCT02091375

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder | NCT04197102

CBD Oil for Reducing Emotional Impact of COVID-19 (CBDOIL) | NCT04603781

Articles citing this ↘

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med (2017) 1.39

Cannabinoids for Epilepsy - Real Data, at Last. N Engl J Med (2017) 0.75

Anticonvulsant Effects of Cannabidiol in Dravet Syndrome. Epilepsy Curr (1) 0.75